Umang Swami, MD, on Prostate Cancer: Differences in Genomic, Transcriptomic, and Immune Landscape Based on Site of Metastasis
2024 ASCO GU Cancers Symposium
Umang Swami, MD, of Huntsman Cancer Institute at the University of Utah, describes the molecular and immunologic mechanisms of metastatic tropism in advanced prostate cancer, data that may facilitate future drug development. In patients with metastatic disease, specific sites are associated with differential overall survival, but the biological reasons have not been fully explored (Abstract 21).
The ASCO Post Staff
Saby George, MD, of Roswell Park Comprehensive Cancer Center, discusses pharmacokinetics, efficacy, and safety results from CheckMate 67T, a phase III trial comparing the use of subcutaneous vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who have received prior systemic therapy (Abstract LBA360).
The ASCO Post Staff
Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and limited therapeutic options. According to Dr. Grande, the existence of long-lasting responders makes it worthwhile to continue investigating predictive factors that may help to select patients for this combination therapy (Abstract 1).
The ASCO Post Staff
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses results of the CONTACT-2 trial, which showed cabozantinib plus atezolizumab improved radiographic progression–free survival of patients with metastatic castration-resistant prostate cancer vs a second novel hormonal therapy (NHT) in patients who had experienced disease progression on a prior NHT and have extrapelvic nodal or visceral disease. The benefits were more pronounced in patients with liver metastasis and in those who previously received docetaxel (Abstract 18).
The ASCO Post Staff
Rohit K. Jain, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses a novel phase II trial of pembrolizumab plus cabozantinib. The study showed this combination may be efficacious as first-line therapy for patients with metastatic urothelial carcinoma, including those who are ineligible for cisplatin. Further investigation with a focus on predictive biomarkers is ongoing (Abstract 539).
The ASCO Post Staff
Amanda Nizam, MD, of the Cleveland Clinic, discusses results from the UNITE study, which shows patients with advanced urothelial cancer who were treated with enfortumab vedotin-ejfv (EV) after switch maintenance avelumab had outcomes consistent with data with EV in platinum- and immune checkpoint inhibitor–refractory disease (Abstract 537).
